View Older Stories View More Recent Stories
-
Citius Announces Pricing of $7.0 Million Underwritten Offering Priced At-the-Market
-
Citius Pharmaceuticals (CTXR) Announces Change to Primary Endpoint In Mino-Lok Phase 3 Study
-
Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study
-
Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith.
-
Citius Pharmaceuticals (CTXR) PT Lowered to $1.65 at H.C. Wainwright
-
Citius Provides Developmental Plans for Mino-Wrap
-
Citius Pharmaceuticals' Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris
-
Citius Pharmaceuticals to Present at the ThinkEquity Conference
-
Citius Pharmaceuticals Presents Data on Mino-Lok® Showing 98% Clinical Efficacy
-
Citius Pharmaceuticals Successfully Raises $5.3 Million
-
Citius Pharmaceuticals (CTXR) Announces $5.3 Million Registered Direct Offering of Common Stock Priced At-the-Market
-
Citius Announces $5.3 Million Registered Direct Offering Priced At-the-Market
-
Citius Provides Update on Its CITI Platforms and Gives Investors Further Insight on their Licensing Agreement with MD Anderson Cancer Center
-
Citius Pharmaceuticals to Present at NobleCon15 Investor Conference
-
Citius Licenses Mino-Wrap From MD Anderson Cancer Center
-
Citius Pharmaceuticals to Present at Biotech Showcase Investor Conference
-
Citius Pharmaceuticals (CTXR) Reports Update on Mino-Lok and CITI-002
-
Citius Pharmaceuticals Provides Updates on Mino-Lok® and CITI-002
-
Citius Pharmaceuticals to Present at the 11th Annual LD Micro Main Event
-
Citius Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
-
Citius Reports On Activities During Infectious Disease Week 2018
-
Citius Announces The Publication Of European Patent For Mino-Lok®
-
Citius Announces The Issuance Of The Patent On The Advanced Stability Of Mino-Lok® By USPTO
-
Citius Pharmaceuticals Successfully Raises $10 Million
-
Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market
-
Citius Pharmaceuticals (CTXR) Prices 7.843M Share Offering at Approx. $10M
-
Citius Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market
-
Citius Pharmaceuticals (CTXR) Granted Notice Of Allowance from USPTO on Advanced Stability Patent Application For Mino-Lok
-
Citius Announces The Notice Of Allowance From The USPTO On The Advanced Stability Patent Application For Mino-Lok®
-
Citius Announces Key Addition to its Scientific Advisory Board
-
Citius Pharmaceuticals (CTXR) Announces Clinical Update And Progress of Mino-Lok Phase 3 Trial
-
Citius Provides Clinical Update And Progress Of The Mino-Lok® Phase 3 Trial
-
Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark
-
Citius Pharmaceuticals (CTXR) Announces $2 Million Registered Direct Offering Priced At-the-Market
-
Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market
-
Citius Reports Progress in Hemorroid Treatment Program
-
Citius Pharmaceuticals (CTXR) Reports Enrollment Of First Patient In The Mino-Lok Phase 3 Trial
-
Citius Announces Enrollment Of First Patient In The Mino-Lok™ Phase 3 Trial
-
Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias
-
Citius Pharmaceuticals to Present at BIO CEO & Investor Conference
-
Citius Pharmaceuticals to Present at Biotech Showcase™ 2018
-
Citius Pharmaceuticals (CTXR) Announces 1.28M Share Common Offering at $4.69/Sh
-
Citius Announces $6 Million Registered Direct Offering Priced At-the-Market
-
Citius Pharmaceuticals to Present at the 10th Annual LD Micro Invitational
-
Citius Pharmaceuticals, Inc. Receives "Fast Track" Designation By FDA For Mino-Lok™ Investigational Trial
-
Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference
-
Citius Pharmaceuticals (CTXR) Discusses Recent developments, Financial Results in Shareholder Letter
-
Citius Pharmaceuticals Issues Shareholder Letter
-
Citius Pharmaceuticals (CTXR) Halted on LUDP
-
Citius Pharmaceuticals (CTXR) Reports Phase 3 Update On Mino-Lok Clinical Trial Following FDA Meeting

